Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Results of Operations and Financial ConditionItem 2.02
Recro Pharma, Inc. (the “Company”) is currently in the process of finalizing its financial results for the fiscal year ended December31, 2017. Based on information currently available, the Company estimates that, as of December31, 2017, cash and cash equivalents were approximately $64.0million.
The Company’s estimate of its cash and cash equivalents as of December31, 2017 is an estimate prepared by management in good faith based upon internal reporting and expectations as of and for the year ended December31, 2017. This estimate is preliminary, and unaudited, and may be revised as a result of management’s further review of the Company’s results. Neither the Company nor its auditors have completed the year end procedures as of and for the year ended December31, 2017, and there can be no assurance that the Company’s final results for this period will not differ from this estimate. The Company’s actual results may differ materially from these estimates due to the completion of its financial closing procedures, final adjustments and other developments that may arise between now and the time the financial results are finalized.
The information set forth under this Item shall be deemed to be filed for purposes of Section18 of the Securities Exchange Act of 1934.
On February7, 2018, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form8-Kand is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.
| Item 2.02 | Financial Statements and Exhibits. |
(d)Exhibits
The following exhibits are being filed herewith:
| Exhibit No. |
Document |
| 99.1 | Investor Presentation of Recro Pharma, Inc. |
Recro Pharma, Inc. ExhibitEX-99.1 2 d442079dex991.htm EX-99.1 EX-99.1 February 2018 Relieving pain…….Improving lives Exhibit 99.1 Special Note Regarding Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements,…To view the full exhibit click here
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.